An objective case definition of lipodystrophy in HIV-infected adults: a case-control study (Q44350196)

2 December 2017

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study (English)

1 reference

2 December 2017

0 references

S Emery

2

0 references

author name string

A Carr

1

1 reference

2 December 2017

M Law

3

1 reference

2 December 2017

R Puls

4

1 reference

2 December 2017

J D Lundgren

5

1 reference

2 December 2017

W G Powderly

6

1 reference

2 December 2017

HIV Lipodystrophy Case Definition Study Group

7

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

2 December 2017

1 reference

2 December 2017

361

1 reference

2 December 2017

726-735

1 reference

2 December 2017

9359

1 reference

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

2 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

"Buffalo hump" in men with HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Clinical assessment of HIV-associated lipodystrophy in an ambulatory population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Insulin resistance in HIV protease inhibitor-associated diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Highly active antiretroviral therapy and coronary heart disease: the need for perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Sonographic assessment of regional fat in HIV-1-infected people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Effects of antiretroviral drug combinations on the differentiation of adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Clinical guidelines: developing guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Developing case definitions for symptom-based conditions: the problem of specificity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912656-6

7 January 2021

10.1016/S0140-6736(03)12656-6

Identifiers

DOI

1 reference

2 December 2017

1 reference